The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform
Mehmet Karahan - One of the best experts on this subject based on the ideXlab platform.
-
preoperative Neutrophil Lymphocyte Ratio and saphenous vein graft patency after coronary artery bypass grafting
Clinical and Applied Thrombosis-Hemostasis, 2014Co-Authors: İrfan Taşoğlu, Osman Turak, Yunus Nazli, Firat Ozcan, Necmettin Colak, Serpil Sahin, Kemal Kavasoglu, Bahadir Genc, Dogan Emre Sert, Mehmet KarahanAbstract:AIM: The aim of the present study was to investigate the predictive value of preoperative Neutrophil-Lymphocyte Ratio (NLR) in postoperative saphenous vein graft patency in patients undergoing coronary artery bypass grafting (CABG) surgery. METHOD: We retrospectively analyzed 444 patients who had undergone CABG and a further control coronary angiography due to recurrence of symptoms. The patients were divided into tertile groups according to the NLR. The primary end point was 50% saphenous vein graft stenosis or more or complete occlusion. RESULT: The saphenous vein graft failure in the 3 groups based on NLR was 33%, 66.2%, and 79.1%, in the low-, middle- and high-risk groups, respectively. In multivariate regression modeling, current smoker, diabetes mellitus, target artery diameter <1.5 mm, and NLR independently predicted saphenous vein graft patency in patients after CABG. CONCLUSION: Preoperative NLR is clearly an independent predictor of saphenous vein graft patency in patients after CABG.
-
preoperative Neutrophil Lymphocyte Ratio and saphenous vein graft patency after coronary artery bypass grafting
Clinical and Applied Thrombosis-Hemostasis, 2014Co-Authors: İrfan Taşoğlu, Osman Turak, Yunus Nazli, Firat Ozcan, Necmettin Colak, Serpil Sahin, Kemal Kavasoglu, Bahadir Genc, Dogan Emre Sert, Mehmet KarahanAbstract:Aim:The aim of the present study was to investigate the predictive value of preoperative Neutrophil–Lymphocyte Ratio (NLR) in postoperative saphenous vein graft patency in patients undergoing coron...
Udai Banerji - One of the best experts on this subject based on the ideXlab platform.
-
Neutrophil Lymphocyte Ratio kinetics in patients with advanced solid tumours on phase i trials of pd 1 pd l1 inhibitors
European Journal of Cancer, 2018Co-Authors: Malaka Ameratunga, Maxime Chenardpoirier, Irene Moreno Candilejo, Manuel Pedregal, David Dolling, Caterina Aversa, Alvaro Henrique Ingles Garces, Udai Banerji, S B KayeAbstract:Abstract Background Although the Neutrophil-Lymphocyte Ratio (NLR) is prognostic in many oncological settings, its significance in the immunotherapy era is unknown. Mechanistically, PD-1/PD-L1 inhibitors may alter NLR. We sought to characterise NLR kinetics in patients with advanced solid tumours treated with PD-1/PD-L1 inhibitors. Methods Electronic records of patients treated with PD-1/PD-L1 inhibitors on phase I trials across three sites were reviewed. A high NLR (hNLR) was predefined as >5. Univariate logistic regression models were used for toxicity, response analyses and Cox models for overall survival (OS) and progression-free survival analyses. Landmark analyses were performed (cycle two, three). Longitudinal analysis of NLR was performed utilising a mixed effect regression model. Results The median OS for patients with hNLR was 8.5 months and 19.4 for patients with low NLR, (hazard Ratio [HR] = 1.85, 95% confidence interval [CI] 1.15–2.96, p = 0.01). On landmark analysis, hNLR was significantly associated with inferior OS at all time points with a similar magnitude of effect over time (p Conclusions hNLR at baseline and during treatment is adversely prognostic in patients with advanced malignancies receiving PD-1/PD-L1 blockade. Importantly, NLR reduced over time in responders to immunotherapy. Taken together, these data suggest that baseline and longitudinal NLR may have utility as a unique biomarker to aid clinical decision-making in patients receiving immunotherapy.
-
Neutrophil Lymphocyte Ratio kinetics in patients with advanced solid tumours on phase i trials of pd 1 pd l1 inhibitors
European Journal of Cancer, 2018Co-Authors: Malaka Ameratunga, Maxime Chenardpoirier, Irene Moreno Candilejo, Manuel Pedregal, David Dolling, Caterina Aversa, Alvaro Henrique Ingles Garces, Andrew Lui, Joo Ern Ang, Udai BanerjiAbstract:Abstract Background Although the Neutrophil-Lymphocyte Ratio (NLR) is prognostic in many oncological settings, its significance in the immunotherapy era is unknown. Mechanistically, PD-1/PD-L1 inhibitors may alter NLR. We sought to characterise NLR kinetics in patients with advanced solid tumours treated with PD-1/PD-L1 inhibitors. Methods Electronic records of patients treated with PD-1/PD-L1 inhibitors on phase I trials across three sites were reviewed. A high NLR (hNLR) was predefined as >5. Univariate logistic regression models were used for toxicity, response analyses and Cox models for overall survival (OS) and progression-free survival analyses. Landmark analyses were performed (cycle two, three). Longitudinal analysis of NLR was performed utilising a mixed effect regression model. Results The median OS for patients with hNLR was 8.5 months and 19.4 for patients with low NLR, (hazard Ratio [HR] = 1.85, 95% confidence interval [CI] 1.15–2.96, p = 0.01). On landmark analysis, hNLR was significantly associated with inferior OS at all time points with a similar magnitude of effect over time (p Conclusions hNLR at baseline and during treatment is adversely prognostic in patients with advanced malignancies receiving PD-1/PD-L1 blockade. Importantly, NLR reduced over time in responders to immunotherapy. Taken together, these data suggest that baseline and longitudinal NLR may have utility as a unique biomarker to aid clinical decision-making in patients receiving immunotherapy.
Maxime Chenardpoirier - One of the best experts on this subject based on the ideXlab platform.
-
Neutrophil Lymphocyte Ratio kinetics in patients with advanced solid tumours on phase i trials of pd 1 pd l1 inhibitors
European Journal of Cancer, 2018Co-Authors: Malaka Ameratunga, Maxime Chenardpoirier, Irene Moreno Candilejo, Manuel Pedregal, David Dolling, Caterina Aversa, Alvaro Henrique Ingles Garces, Udai Banerji, S B KayeAbstract:Abstract Background Although the Neutrophil-Lymphocyte Ratio (NLR) is prognostic in many oncological settings, its significance in the immunotherapy era is unknown. Mechanistically, PD-1/PD-L1 inhibitors may alter NLR. We sought to characterise NLR kinetics in patients with advanced solid tumours treated with PD-1/PD-L1 inhibitors. Methods Electronic records of patients treated with PD-1/PD-L1 inhibitors on phase I trials across three sites were reviewed. A high NLR (hNLR) was predefined as >5. Univariate logistic regression models were used for toxicity, response analyses and Cox models for overall survival (OS) and progression-free survival analyses. Landmark analyses were performed (cycle two, three). Longitudinal analysis of NLR was performed utilising a mixed effect regression model. Results The median OS for patients with hNLR was 8.5 months and 19.4 for patients with low NLR, (hazard Ratio [HR] = 1.85, 95% confidence interval [CI] 1.15–2.96, p = 0.01). On landmark analysis, hNLR was significantly associated with inferior OS at all time points with a similar magnitude of effect over time (p Conclusions hNLR at baseline and during treatment is adversely prognostic in patients with advanced malignancies receiving PD-1/PD-L1 blockade. Importantly, NLR reduced over time in responders to immunotherapy. Taken together, these data suggest that baseline and longitudinal NLR may have utility as a unique biomarker to aid clinical decision-making in patients receiving immunotherapy.
-
Neutrophil Lymphocyte Ratio kinetics in patients with advanced solid tumours on phase i trials of pd 1 pd l1 inhibitors
European Journal of Cancer, 2018Co-Authors: Malaka Ameratunga, Maxime Chenardpoirier, Irene Moreno Candilejo, Manuel Pedregal, David Dolling, Caterina Aversa, Alvaro Henrique Ingles Garces, Andrew Lui, Joo Ern Ang, Udai BanerjiAbstract:Abstract Background Although the Neutrophil-Lymphocyte Ratio (NLR) is prognostic in many oncological settings, its significance in the immunotherapy era is unknown. Mechanistically, PD-1/PD-L1 inhibitors may alter NLR. We sought to characterise NLR kinetics in patients with advanced solid tumours treated with PD-1/PD-L1 inhibitors. Methods Electronic records of patients treated with PD-1/PD-L1 inhibitors on phase I trials across three sites were reviewed. A high NLR (hNLR) was predefined as >5. Univariate logistic regression models were used for toxicity, response analyses and Cox models for overall survival (OS) and progression-free survival analyses. Landmark analyses were performed (cycle two, three). Longitudinal analysis of NLR was performed utilising a mixed effect regression model. Results The median OS for patients with hNLR was 8.5 months and 19.4 for patients with low NLR, (hazard Ratio [HR] = 1.85, 95% confidence interval [CI] 1.15–2.96, p = 0.01). On landmark analysis, hNLR was significantly associated with inferior OS at all time points with a similar magnitude of effect over time (p Conclusions hNLR at baseline and during treatment is adversely prognostic in patients with advanced malignancies receiving PD-1/PD-L1 blockade. Importantly, NLR reduced over time in responders to immunotherapy. Taken together, these data suggest that baseline and longitudinal NLR may have utility as a unique biomarker to aid clinical decision-making in patients receiving immunotherapy.
Malaka Ameratunga - One of the best experts on this subject based on the ideXlab platform.
-
Neutrophil Lymphocyte Ratio kinetics in patients with advanced solid tumours on phase i trials of pd 1 pd l1 inhibitors
European Journal of Cancer, 2018Co-Authors: Malaka Ameratunga, Maxime Chenardpoirier, Irene Moreno Candilejo, Manuel Pedregal, David Dolling, Caterina Aversa, Alvaro Henrique Ingles Garces, Udai Banerji, S B KayeAbstract:Abstract Background Although the Neutrophil-Lymphocyte Ratio (NLR) is prognostic in many oncological settings, its significance in the immunotherapy era is unknown. Mechanistically, PD-1/PD-L1 inhibitors may alter NLR. We sought to characterise NLR kinetics in patients with advanced solid tumours treated with PD-1/PD-L1 inhibitors. Methods Electronic records of patients treated with PD-1/PD-L1 inhibitors on phase I trials across three sites were reviewed. A high NLR (hNLR) was predefined as >5. Univariate logistic regression models were used for toxicity, response analyses and Cox models for overall survival (OS) and progression-free survival analyses. Landmark analyses were performed (cycle two, three). Longitudinal analysis of NLR was performed utilising a mixed effect regression model. Results The median OS for patients with hNLR was 8.5 months and 19.4 for patients with low NLR, (hazard Ratio [HR] = 1.85, 95% confidence interval [CI] 1.15–2.96, p = 0.01). On landmark analysis, hNLR was significantly associated with inferior OS at all time points with a similar magnitude of effect over time (p Conclusions hNLR at baseline and during treatment is adversely prognostic in patients with advanced malignancies receiving PD-1/PD-L1 blockade. Importantly, NLR reduced over time in responders to immunotherapy. Taken together, these data suggest that baseline and longitudinal NLR may have utility as a unique biomarker to aid clinical decision-making in patients receiving immunotherapy.
-
Neutrophil Lymphocyte Ratio kinetics in patients with advanced solid tumours on phase i trials of pd 1 pd l1 inhibitors
European Journal of Cancer, 2018Co-Authors: Malaka Ameratunga, Maxime Chenardpoirier, Irene Moreno Candilejo, Manuel Pedregal, David Dolling, Caterina Aversa, Alvaro Henrique Ingles Garces, Andrew Lui, Joo Ern Ang, Udai BanerjiAbstract:Abstract Background Although the Neutrophil-Lymphocyte Ratio (NLR) is prognostic in many oncological settings, its significance in the immunotherapy era is unknown. Mechanistically, PD-1/PD-L1 inhibitors may alter NLR. We sought to characterise NLR kinetics in patients with advanced solid tumours treated with PD-1/PD-L1 inhibitors. Methods Electronic records of patients treated with PD-1/PD-L1 inhibitors on phase I trials across three sites were reviewed. A high NLR (hNLR) was predefined as >5. Univariate logistic regression models were used for toxicity, response analyses and Cox models for overall survival (OS) and progression-free survival analyses. Landmark analyses were performed (cycle two, three). Longitudinal analysis of NLR was performed utilising a mixed effect regression model. Results The median OS for patients with hNLR was 8.5 months and 19.4 for patients with low NLR, (hazard Ratio [HR] = 1.85, 95% confidence interval [CI] 1.15–2.96, p = 0.01). On landmark analysis, hNLR was significantly associated with inferior OS at all time points with a similar magnitude of effect over time (p Conclusions hNLR at baseline and during treatment is adversely prognostic in patients with advanced malignancies receiving PD-1/PD-L1 blockade. Importantly, NLR reduced over time in responders to immunotherapy. Taken together, these data suggest that baseline and longitudinal NLR may have utility as a unique biomarker to aid clinical decision-making in patients receiving immunotherapy.
İrfan Taşoğlu - One of the best experts on this subject based on the ideXlab platform.
-
preoperative Neutrophil Lymphocyte Ratio and saphenous vein graft patency after coronary artery bypass grafting
Clinical and Applied Thrombosis-Hemostasis, 2014Co-Authors: İrfan Taşoğlu, Osman Turak, Yunus Nazli, Firat Ozcan, Necmettin Colak, Serpil Sahin, Kemal Kavasoglu, Bahadir Genc, Dogan Emre Sert, Mehmet KarahanAbstract:AIM: The aim of the present study was to investigate the predictive value of preoperative Neutrophil-Lymphocyte Ratio (NLR) in postoperative saphenous vein graft patency in patients undergoing coronary artery bypass grafting (CABG) surgery. METHOD: We retrospectively analyzed 444 patients who had undergone CABG and a further control coronary angiography due to recurrence of symptoms. The patients were divided into tertile groups according to the NLR. The primary end point was 50% saphenous vein graft stenosis or more or complete occlusion. RESULT: The saphenous vein graft failure in the 3 groups based on NLR was 33%, 66.2%, and 79.1%, in the low-, middle- and high-risk groups, respectively. In multivariate regression modeling, current smoker, diabetes mellitus, target artery diameter <1.5 mm, and NLR independently predicted saphenous vein graft patency in patients after CABG. CONCLUSION: Preoperative NLR is clearly an independent predictor of saphenous vein graft patency in patients after CABG.
-
preoperative Neutrophil Lymphocyte Ratio and saphenous vein graft patency after coronary artery bypass grafting
Clinical and Applied Thrombosis-Hemostasis, 2014Co-Authors: İrfan Taşoğlu, Osman Turak, Yunus Nazli, Firat Ozcan, Necmettin Colak, Serpil Sahin, Kemal Kavasoglu, Bahadir Genc, Dogan Emre Sert, Mehmet KarahanAbstract:Aim:The aim of the present study was to investigate the predictive value of preoperative Neutrophil–Lymphocyte Ratio (NLR) in postoperative saphenous vein graft patency in patients undergoing coron...
-
usefulness of Neutrophil Lymphocyte Ratio as a predictor of amputation after embolectomy for acute limb ischemia
Annals of Vascular Surgery, 2014Co-Authors: İrfan Taşoğlu, Necmettin Colak, Dogan Emre Sert, Omer Faruk Cicek, Gokhan Lafci, Ersin Kadirogullari, Asli Demir, Umut Cavus, Murat Songur, Bledar HodoAbstract:Background The aim of this study was to examine the predictive ability of admission Neutrophil/Lymphocyte Ratio (NLR) for predicting amputation in patients with acute limb ischemia who underwent embolectomy. Methods We retrospectively analyzed the clinical, hematologic, and amputation data of 254 patients who had undergone embolectomy for acute limb ischemia. There were 152 (52%) men and 93 (48%) women, with a mean age of 66.04 ± 13.30 years. The admission NLR was determined by dividing the absolute Neutrophil count by the absolute Lymphocyte count. The primary end point was determined as amputation and death. Results The mean duRation of follow-up was 26 months. During the follow-up period, there were 18 (7%) amputations within 30 days of surgery and 36 (15%) amputations over a mean follow-up of 26 months. Based on multivariate logistic regression modeling, no arterial back bleeding and preoperative NLR were observed to be independent risk factors for amputation within 30 days of surgery, and no arterial back bleeding and preoperative NLR were observed to be independent risk factors for midterm amputation for the same time period. A NLR of ≥5.2 was taken as the cutoff based upon the receiver operating characteristic. In receiver operating characteristic curve analysis, a NLR ≥5.2 had 83% sensitivity and 63% specificity in predicting amputation within 30 days of surgery and 63% sensitivity and 63% specificity in predicting midterm amputation. Conclusions An elevated NLR is associated with a poorer limb survival after embolectomy. This simple, inexpensive test may therefore be added to risk stratification of these high-risk patients.